Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment

International Journal of Alzheimer's Disease

Volumn 2015, Issue , 2015, Pages

  McCaulley, Mark E ^a   Grush, Kira A ^a  

^a Yampa Valley Medical Assoc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; METHANESULFONYL FLUORIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALZHEIMER DISEASE; BIOME; BLOOD BRAIN BARRIER; BRAIN DISEASE; CEREBROVASCULAR ACCIDENT; EVIDENCE BASED PRACTICE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADICULOPATHY; REVIEW; SPINAL CORD DISEASE; SPINE DISEASE; TRAUMATIC BRAIN INJURY;

EID: 84948823160     PISSN: 20908024     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2015/515248     Document Type: Review

References (89)

1. G. P. Morris, I. A. Clark, and B. Vissel, "Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease," Acta Neuropathologica Communications, vol. 2, no. 1, article 135, 2014.
2. D. A. Drachman, "The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer'sdisease," Alzheimer's and Dementia, vol. 10, no. 3, pp. 372-380, 2014.
3. T. Ishii, S. Haga, and F. Shimizu, "Identification of components of immunoglobulins in senile plaques by means of fluorescent antibody technique," Acta Neuropathologica, vol. 32, no. 2, pp. 157-162, 1975.
4. T. Ishii and S. Haga, "Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques," Acta Neuropathologica, vol. 63, no. 4, pp. 296-300, 1984.
5. H. Fillit, W. Ding, L. Buee et al., "Elevated circulating tumor necrosis factor levels in Alzheimer's disease," Neuroscience Letters, vol. 129, no. 2, pp. 318-320, 1991.
6. E. H. Corder, A. M. Saunders, W. J. Strittmatter et al., "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families," Science, vol. 261, no. 5123, pp. 921-923, 1993.
7. M. Malik, I. Parikh, J. B. Vasquez et al., "Genetics ignite focus on microglial inflammation in Alzheimer's disease," Molecular Neurodegeneration, vol. 10, no. 1, article 52, 2015.
8. J. Rogers, S. Webster, L. Lue et al., "Inflammation and Alzheimer's disease pathogenesis," Neurobiology of Aging, vol. 17, no. 5, pp. 681-686, 1996.
9. S. Kook,H. SeokHong, M. Moon, and I. Mook-Jung, "Disruption of blood-brain barrier in Alzheimer disease pathogenesis," Tissue Barriers, vol. 1, no. 2, Article ID e23993, 2014.
10. A. P. Sagare, R. D. Bell, and B. V. Zlokovic, "Neurovascular dysfunction and faulty amyloid-peptide clearance in Alzheimer disease," Cold Spring Harbor Perspectives inMedicine, vol. 2, no. 10, Article ID a011452, 2012.
11. L. Claudio, "Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients," Acta Neuropathologica, vol. 91, no. 1, pp. 6-14, 1996.
12. Alzheimer's Association, "2014 Alzheimer's disease facts and figures," Alzheimer's & Dementia, vol. 10, no. 2, pp. e47-e92, 2014.
13. B. Obermeier, R. Daneman, and R. M. Ransohoff, "Development, maintenance and disruption of the blood-brain barrier," Nature Medicine, vol. 19, no. 12, pp. 1584-1596, 2013.
14. J. M. Lehmann, J. M. Lenhard,B. B. Oliver, G. M. Ringold, andS. A. Kliewer, "Peroxisome proliferator-activated receptors and are activated by indomethacin and other non-steroidal antiinflammatory drugs,"The Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406-3410, 1997.
15. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor-is a negative regulator of macrophage activation," Nature, vol. 391, no. 6662, pp. 79-82, 1998.
16. B. Leveugle and H. Fillit, "Proteoglycans and the acute-phase response in Alzheimer's disease brain,"Molecular Neurobiology, vol. 9, no. 1-3, pp. 25-32, 1994.
17. B. A. In 'T Veld, A. Ruitenberg, A. Hofman et al., "Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease," The New England Journal of Medicine, vol. 345, no. 21, pp. 1515-1521, 2001.
18. J. C. Breitner, L. D. Baker, T. J. Montine et al., "Extended results of the Alzheimer's disease anti-inflammatory prevention trial," Alzheimer's & Dementia, vol. 7, no. 4, pp. 402-411, 2011.
19. M. Etminan, S. Gill, and A. Samii, "Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies," British Medical Journal, vol. 327, no. 7407, article 128, 2003.
20. D. W. Dodick, "Indomethacin-responsive headache syndromes," Current Pain and Headache Reports, vol. 8, no. 1, pp. 19-26, 2004.
21. O. Summ and S. Evers, "Mechanism of action of indomethacin in indomethacin-responsive headaches," Current Pain and Headache Reports, vol. 17, no. 4, article 327, 2013.
22. J. Rogers, L. C. Kirby, S. R. Hempelman et al., "Clinical trial of indomethacin in Alzheimer's disease," Neurology, vol. 43, no. 8, pp. 1609-1611, 1993.
23. D. de Jong, R. Jansen, W. Hoefnagels et al., "No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial," PLoS ONE, vol. 3, no. 1, Article ID e1475, 2008.
24. S. E. Nilsson, B. Johansson, S. Takkinen et al., "Does aspirin protect against Alzheimer's dementia A study in a Swedish population-based sample aged 80 years," European Journal of Clinical Pharmacology, vol. 59, no. 4, pp. 313-319, 2003.
25. S. Kern, I. Skoog, S. Ostling, J. Kern, and A. Börjesson-Hanson, "Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women," BMJ Open, vol. 2, no. 5,Article ID e001288, 2012.
26. J. H. Kang, N. Cook, J. Manson, J. E. Buring, and F. Grodstein, "Low dose aspirin and cognitive function in the women's health study cognitive cohort," British Medical Journal, vol. 334, no. 7601, article 987, 2007.
27. AD Collaborative Group, "Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial," The Lancet Neurology, vol. 7, no. 1, pp. 41-49, 2008.
28. H. Thoonsen, E. Richard, P. Bentham et al., "Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern" Stroke, vol. 41, no. 11, pp. 2690-2692, 2010.
29. Steering Committee of the Physicians' Health Study Research Group, "Final report on the aspirin component of the ongoing Physicians'Health Study,"The New England Journal ofMedicine, vol. 321, no. 3, pp. 129-135, 1989.
30. V. Sharma, V. Thakur, S. N. Singh, and R. Guleria, "Tumor necrosis factor and Alzheimer's disease: a cause and consequence relationship," Bulletin of Clinical Psychopharmacology, vol. 22, no. 1, pp. 86-89, 2012.
31. R. Li, L. Yang, K. Lindholm et al., "Tumor necrosis factor death receptor signaling cascade is required for amyloid-proteininduced neuron death," The Journal of Neuroscience, vol. 24, no. 7, pp. 1760-1771, 2004.
32. M. Pickering,D. Cumiskey, and J. J. O'Connor, "Actions of TNF-on glutamatergic synaptic transmission in the central nervous system," Experimental Physiology, vol. 90, no. 5, pp. 663-670, 2005.
33. L. Aloe, M. Fiore, L. Probert, P. Turrini, and P. Tirassa, "Overexpression of tumour necrosis factor in the brain of transgenic mice differentially alters nerve growth factor levels and choline acetyltransferase activity," Cytokine, vol. 11,no. 1, pp. 45-54, 1999.
34. G. Olmos and J. Lladó, "Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity," Mediators of Inflammation, vol. 2014,Article ID 861231, 12 pages, 2014.
35. J.-Q. Shi, W. Shen, J. Chen et al., "Anti-TNF-reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains," Brain Research, vol. 1368, pp. 239-247, 2011.
36. Q.-H. Zhou, R. Sumbria, E. K.-W. Hui, J. Z. Lu, R. J. Boado, and W. M. Pardridge, "Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor," Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 2, pp. 618-623, 2011.
37. E. Tobinick, "Perispinal etanercept for treatment of Alzheimers disease," Current Alzheimer Research, vol. 4, no. 5, pp. 550-552, 2007.
38. E. L. Tobinick, K. Chen, and X. Chen, "Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging," BMC Research Notes, vol. 2, no. 1, article 28, 2009.
39. E. Tobinick, "Tumour necrosis factor modulation for treatment of Alzheimer's disease," CNS Drugs, vol. 23, no. 9, pp. 713-725, 2009.
40. E. L. Tobinick and H. Gross, "Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration," Journal of Neuroinflammation, vol. 5, no. 1, article 2, 2008.
41. E. Tobinick, H. Gross, A. Weinberger, and H. Cohen, "TNFalpha modulation for treatment of Alzheimer's disease: a 6-month pilot study," Medscape General Medicine, vol. 8, no. 2, article 25, 2006.
42. J.-Q. Shi, B.-R. Wang, W.-W. Jiang et al., "Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's Disease," Journal of the American Geriatrics Society, vol. 59, no. 6, pp. 1142-1144, 2011.
43. W. S. T. Griffin, "Perispinal etanercept: potential as an Alzheimer therapeutic," Journal of Neuroinflammation, vol. 5, no. 1, article 3, 2008.
44. J. Butchart, L. Brook,V. Hopkins et al., "Etanercept inAlzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial," Neurology, vol. 84, no. 21, pp. 2161-2168, 2015.
45. K. L. Lambertsen, K. Biber, and B. Finsen, "Inflammatory cytokines in experimental and human stroke," Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 9, pp. 1677-1698, 2012.
46. K. L. Lambertsen, M. Meldgaard, R. Ladeby, and B. Finsen, "A quantitative study of microglial-macrophage synthesis of tumor necrosis factor during acute and late focal cerebral ischemia in mice," Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 1, pp. 119-135, 2005.
47. B. Lei, H. N. Dawson, B. Roulhac-Wilson, H. Wang, D. T. Laskowitz, andM. L. James, "Tumornecrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage," Journal of Neuroinflammation, vol. 10, article 103, 2013.
48. B. H. Clausen, M. Degn, N. A. Martin et al., "Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia," Journal of Neuroinflammation, vol. 11, no. 1, article 203, 2014.
49. E. Tobinick, N. M. Kim, G. Reyzin, H. Rodriguez-Romanacce, and V. Depuy, "Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept," CNS Drugs, vol. 26, no. 12, pp. 1051-1070, 2012.
50. T. A. Ignatowski, R. N. Spengler, K. M. Dhandapani, H. Folkersma, R. F. Butterworth, and E. Tobinick, "Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence," CNS Drugs, vol. 28, no. 8, pp. 679-697, 2014.
51. A. Tuttolomondo, R. Pecoraro, and A. Pinto, "Studies of selective TNF inhibitors in the treatment of brain injury fromstroke and trauma: a review of the evidence to date," Drug Design, Development andTherapy, vol. 8, pp. 2221-2239, 2014.
52. T. Igarashi, S. Kikuchi, V. Shubayev, and R. R. Myers, "Exogenous tumor necrosis factor-alpha mimics nucleus pulposusinduced neuropathology: molecular, histologic, and behavioral comparisons in rats," Spine, vol. 25, no. 23, pp. 2975-2980, 2000.
53. R. Wagner and R. R. Myers, "Endoneurial injection of TNF-produces neuropathic pain behaviors," NeuroReport, vol. 7, no. 18, pp. 2897-2901, 1996.
54. E. L. Tobinick and S. Britschgi-Davoodifar, "Perispinal TNF-inhibition for discogenic pain," Swiss Medical Weekly, vol. 133, no. 11-12, pp. 170-177, 2003.
55. B. J. C. Freeman, G. L. Ludbrook, S. Hall et al., "Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation," Spine, vol. 38, no. 23, pp. 1986-1994, 2013.
56. E. C. Beattie, D. Stellwagen, W. Morishita et al., "Control of synaptic strength by glial TNFalpha," Science, vol. 295, no. 5563, pp. 2282-2285, 2002.
57. M. Santello, P. Bezzi, and A. Volterra, "TNF controls glutamatergic gliotransmission in the hippocampal dentate gyrus," Neuron, vol. 69, no. 5, pp. 988-1001, 2011.
58. V. Tancredi, G. D'Arcangelo, F. Grassi et al., "Tumor necrosis factor alters synaptic transmission in rat hippocampal slices," Neuroscience Letters, vol. 146, no. 2, pp. 176-178, 1992.
59. D. Stellwagen, E. C. Beattie, J. Y. Seo, and R. C. Malenka, "Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-," The Journal of Neuroscience, vol. 25, no. 12, pp. 3219-3228, 2005.
60. H. Pribiag andD. Stellwagen, "TNF-downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABAA receptors," Journal of Neuroscience, vol. 33, no. 40, pp. 15879-15893, 2013.
61. M. S. Beeri, J. Schmeidler, G. T. Lesser et al., "Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology," Neurobiology ofAging, vol. 33,no. 7, pp. 1258-1264, 2012.
62. J. M. Alisky, "Intrathecal corticosteroids might slowAlzheimer's disease progression," Neuropsychiatric Disease and Treatment, vol. 4, no. 5, pp. 831-833, 2008.
63. J. C. S. Breitner, B. A. Gau, K. A. Welshet al., "Inverse association of anti-inflammatory treatments andAlzheimer's disease: initial results of a co-twin control study," Neurology, vol. 44, no. 2, pp. 227-232, 1994.
64. H. Koch, A. Szecsey, P. Aisen, M. Grundman, R. Thomas, and L. Thal, "A randomized controlled trial of prednisone in Alzheimer's disease," Neurology, vol. 55, no. 7, p. 1067, 2000.
65. S. J. Lupien, M. de Leon, S. de Santi et al., "Cortisol levels during human aging predict hippocampal atrophy andmemory deficits," Nature Neuroscience, vol. 1, no. 1, pp. 69-73, 1998.
66. F. Naddafi and A. Mirshafiey, "The neglected role of histamine in Alzheimer's disease," American Journal of Alzheimer's Disease & otherDementias, vol. 28, no. 4, pp. 327-336, 2013.
67. P. R. Bharadwaj, K. A. Bates, T. Porter et al., "Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases," Translational Psychiatry, vol. 3, no. 12, article e332, 2013.
68. T. Beach, D. Walker, L. Sue et al., "Immunotoxin lesion of the cholinergic nucleus basalis causes A deposition: towards a physiologic animal model of Alzhemiers Disease," Current Medicinal Chemistry-Immunology, Endocrine and Metabolic Agents, vol. 3, no. 1, pp. 57-75, 200
69. J. E. Walker and S. B. Margolin, "Pirfenidone for chronic progressive multiple sclerosis," Multiple Sclerosis, vol. 7, no. 5, pp. 305-312, 2001.
70. J. D. Bowen, K. Maravilla, and S. B. Margolin, "Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis," Multiple Sclerosis, vol. 9, no. 3, pp. 280-283, 2003.
71. J. E. Walker, S. N. Giri, and S. B. Margolin, "A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis," Multiple Sclerosis, vol. 11, no. 2, pp. 149-158, 2005.
72. R. A. Rudick, D. Miller, S. Hass et al., "Health-related quality of life in multiple sclerosis: effects of natalizumab," Annals of Neurology, vol. 62, no. 4, pp. 335-346, 2007.
73. G. Filippini, C. Del Giovane, L. Vacchi et al., "Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis," Cochrane Database of Systematic Reviews, no. 6, Article ID CD008933, 2013.
74. E. Zintzaras, C. Doxani, T. Mprotsis, C. H. Schmid, and G. M. Hadjigeorgiou, "Network analysis of randomized controlled trials in multiple sclerosis," Clinical Therapeutics, vol. 34, no. 4, pp. 857e9-869e9, 2012.
75. A. Langer-Gould, S. W. Atlas, A. J. Green, A. W. Bollen, and D. Pelletier, "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab," The New England Journal of Medicine, vol. 353, no. 4, pp. 375-381, 2005.
76. G. Bloomgren, S. Richman, C. Hotermans et al., "Risk of natalizumab-associated progressive multifocal leukoencephalopathy," The New England Journal of Medicine, vol. 366, no. 20, pp. 1870-1880, 2012.
77. P. Iaffaldano, R. G. Viterbo, D. Paolicelli et al., "Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study," PloS one, vol. 7, no. 4,Article ID e35843, 2012.
78. X. Cheng, Y. Shen, and R. Li, "Targeting TNF: a therapeutic strategy for Alzheimer's disease," Drug Discovery Today, vol. 19, no. 11, pp. 1822-1827, 2014.
79. F. He and R. Balling, "The role of regulatory T cells in neurodegenerative diseases," Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 5, no. 2, pp. 153-180, 2013.
80. S. D. Bilbo, G. A. Wray, S. E. Perkins, and W. Parker, "Reconstitution of the human biome as the most reasonable solution for epidemics of allergic and autoimmune diseases," Medical Hypotheses, vol. 77, no. 4, pp. 494-504, 2011.
81. I. Ludwig-Portugall and L. E. Layland, "Tlrs, Treg, and B cells, an interplay of regulation during helminth infection," Frontiers in Immunology, vol. 3, article 8, 2012.
82. D. A. Vignali, L. W. Collison, and C. J. Workman, "How regulatory T cells work," Nature Reviews Immunology, vol. 8, no. 7, pp. 523-532, 2008.
83. M. Fox, L. A. Knapp, P. W. Andrews, andC. L. Fincher, "Hygiene and the world distribution of Alzheimer's disease: epidemiological evidence for a relationship between microbial environment and age-adjusted disease burden," Evolution, Medicine, and Public Health, vol. 2013, no. 1, pp. 173-186, 2013.
84. J. J. L. Rodriguez, C. P. Ferri, D. Acosta et al., "Prevalence of dementia in Latin America, India, and China: a populationbased cross-sectional survey," The Lancet, vol. 372, no. 9637, pp. 464-474, 2008.
85. V. Chandra, R. Pandav, H. H. Dodge et al., "Incidence of Alzheimer's disease in a rural community in India: the Indo-US study," Neurology, vol. 57, no. 6, pp. 985-989, 2001.
86. T. L. Cerajewska, M. Davies, and N. X. West, "Periodontitis: a potential risk factor for Alzheimer's disease," British Dental Journal, vol. 218, no. 1, pp. 29-34, 2015.
87. A. R. Kamer, R. G. Craig, A. P. Dasanayake,M. Brys, L. Glodzik-Sobanska, and M. J. de Leon, "Inflammation and Alzheimer's disease: possible role of periodontal diseases," Alzheimer's & Dementia, vol. 4, no. 4, pp. 242-250, 2008.
88. D. E. Moss, P. Berlanga, M. M. Hagan, H. Sandoval, and C. Ishida, "Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type," Alzheimer Disease & Associated Disorders, vol. 13, no. 1, pp. 20-25, 1999.
89. D. E. Moss, R. G. Fariello, J. Sahlmann, I. Sumaya, F. Pericle, and E. Braglia, "A randomized phase I study ofmethanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease," British Journal of Clinical Pharmacology, vol. 75, no. 5, pp. 1231-1239, 2013.